| 產品名稱 | ARH-77 |
|---|---|
| 商品貨號 | B163954 |
| Organism | Homo sapiens, human |
| Tissue | peripheral blood |
| Cell Type | B lymphoblast; Epstein-Barr virus (EBV) transformed |
| Product Format | frozen |
| Morphology | lymphoblast |
| Culture Properties | suspension |
| Biosafety Level | 2 [Herpesvirus; cells contain EBV]
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | plasma cell leukemia |
| Age | 33 years |
| Gender | female |
| Ethnicity | Caucasian |
| Storage Conditions | liquid nitrogen vapor phase |
| Images |  |
| Derivation | The ARH-77 cell line was established from the peripheral blood of a patient suffering from IgG plasma cell leukemia.
Although established from cells taken from a patient with a plasma cell leukemia, this line has been shown to be an EBV-transformed B lymphoblastoid cell line. |
| Clinical Data | 33 years female Caucasian |
| Antigen Expression | CD11a +; CD19 +; CD20 +; CD28 +; CD38 -; CD49e + |
| Comments | The cells are positive for Epstein-Barr nuclear antigen(EBNA +) and Epstein-Barr viral capsid antigen (EBVCA +). The line has been cured of a previous mycoplasma infection. LICR-LON-HMy2 (HMy2), a fast growing mutant of the ARH-77 cell line (ATCC CRL-1621), was irradiated and selected for class I loss to establish the HMy2.C1R (ATCC CRL-1993) cell line. Subsequently, C1R-neo (ATCC CRL-2369), C1R-sB7 (ATCC CRL-2370), and C1R-B7 (ATCC CRL-2371) were established by transfection of the HMy2.C1R cell line. |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing | Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 x 105 viable cells/mL and maintain between 1 x 105 and 1 x 106 cells/mL. |
| Cryopreservation | Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions | Temperature: 37°C |
| STR Profile | D5S818: 10,13 D13S317: 11,13 D7S820: 7,12 D16S539: 9,13 vWA: 17 THO1: 8,9.3 Amelogenin: X TPOX: 8 CSF1PO: 6,10 |
| Isotype | IgG1; kappa light chain |
| Name of Depositor | BD Drewinko |
| Deposited As | Homo sapiens |
| References | Burk KH, et al. Establishment of a human plasma cell line in vitro. Cancer Res. 38: 2508-2513, 1978. PubMed: 566614 Cote RJ, et al. Generation of human monoclonal antibodies reactive with cellular antigens. Proc. Natl. Acad. Sci. USA 80: 2026-2030, 1983. PubMed: 6572959 Storkus WJ, et al. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc. Natl. Acad. Sci. USA 86: 2361-2364, 1989. PubMed: 2784569 Edwards PA, et al. A human-hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemia-derived line. Eur. J. Immunol. 12: 641-648, 1982. PubMed: 7140810 Pellat-Deceunynk C, et al. Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after. Blood 86: 4001-4002, 1995. PubMed: 7579375 Drexler H, et al. False human hematopoietic cell lines: cross-contaminations and misinterpretations. Leukemia 13: 1601-1607, 1999. PubMed: 10516762 Drewinko B, et al. ARH-77, an established human IgG-producing myeloma cell line. I. Morphology, B-cell phenotypic marker profile, and expression of Epstein-Barr virus. Cancer 54: 1883-1892, 1984. PubMed: 6090003 |
| 梅經理 | 17280875617 | 1438578920 |
| 胡經理 | 13345964880 | 2438244627 |
| 周經理 | 17757487661 | 1296385441 |
| 于經理 | 18067160830 | 2088210172 |
| 沈經理 | 19548299266 | 2662369050 |
| 李經理 | 13626845108 | 972239479 |
